abrdn Life Sciences Investors EBIT

abrdn Life Sciences Investors's ebit stands at $150M as of March 2026. That compares with $73M in the prior-year period — up 106.1% year over year. That is above the sector sector average of $-69M. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

abrdn Life Sciences Investors reported $150M in EBIT versus $73M a year earlier — a 106.1% year-over-year increase. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

abrdn Life Sciences Investors sits higher the its sector benchmark ($-69M) with a EBIT of $150M. That is roughly 316.9% above the sector mean. Peer context matters because what looks expensive or cheap in absolute terms can be normal for the sector.

That compares with $73M in the prior-year period — up 106.1% year over year. Sustained growth in EBIT can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how abrdn Life Sciences Investors's EBIT evolved across reporting periods, while the comparison chart places HQL next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.